Here we present real world clinical data evaluating dupilumab as add-on therapy for CSU. We queried our tertiary academic center electronic health record for all patients with an ICD-9/10 code for urticaria with a history of dupilumab use (1/1/2010-6/30/2022). Retrospective chart review ...
Inc. (REGN) announced Friday that the U.S. Food and Drug Administration has accepted for review the resubmission of the supplemental biologics license application or sBLA for Dupixent (dupilumab) to treat chronic spontaneous urticaria or CSU. ...
Paris and Tarrytown, N.Y. February 16, 2024.The Ministry of Health, Labor and Welfare (MHLW) in Japan has granted marketing and manufacturing authorization for Dupixent®(dupilumab) for the treatment of chronic spontaneous urticaria (CSU) in people aged 12 years and older whose disease is not...
Sanofi announced a pivotal phase 3 trial evaluating Dupixent (dupilumab) in patients with moderate-to-severe chronic spontaneous urticaria (CSU), an inflammatory skin disease, met its primary endpoints and all key secondary endpoints at 24 weeks. Adding Dupixent to standard-of-care antihistamines sign...
Two posters presented at the Society for Pediatric Dermatology Annual Meeting explored common health conditions linked to childhood alopecia areata and the effectiveness of dupilumab treatment in children with both alopecia areata and atopic dermatitis. July 19th 2024 Long-Term Oral Corticosteroid Use Linke...
In a phase III study, dupilumab treatment resulted in a significant reduction in pruritus and urticaria scores in antihistamine-resistant CSU patients, while the primary endpoints were not met in omalizumab-resistant patients [69, 70]. Phase II and phase III studies investigating the efficacy of ...
initiation of therapy. Furthermore, dupilumab established its efficacy in case reports regarding patients with bullous pemphigoid (BP) [94,95], chronic refractory pruritus [96] and UP [97]. Clinical trials on the use of dupilumab in chronic spontaneous and cholinergic urticaria are in progress [...
URTICARIAThis article discusses the potential benefits of using dupilumab as a treatment for chronic spontaneous urticaria (CSU) that does not respond to conventional therapies. CSU is a skin disease characterized by wheals and/or angioedema without a known trigger. Dupilumab, an anti-IL4R伪 ...
Emerging targeted therapies on the horizon, such as dupilumab, promise to usher in a new era of highly specific and efficacious treatments. Alternative medicine, stress reduction techniques, and patient education are also important treatment modalities. This review will focus on the mediators of ...
In chronic spontaneous urticaria (CSU), interleukin (IL)-4 and IL-13 may promote mast cell activation directly via IL-4 receptor expression, or indirectly via upregulated immunoglobulin E (IgE) production. Dupilumab significantly improved CSU signs and symptoms in the phase 3, randomized, placebo...